Auflistung Nach Schlagwort "phosphodiesterase IV inhibitor"
Anzeige der Dokumente 1-4 von 4
-
Classification of COPD patients and compliance to recommended treatment in Greece according to GOLD 2017 report: the RELICO study
(2021)Background: Chronic obstructive pulmonary disease (COPD) is a multifactorial clinical condition, characterized by chronic progressive (or worsening) respiratory symptoms, structural pulmonary abnormalities, and impaired ... -
Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of action, clinical applications, current and future perspectives
(2017)Phosphodiesterase (PDE) 4 is a superfamily of enzymes that catalyze the hydrolysis of cyclic adenosine 3', 5'-monophosphate (cAMP), an intracellular second messenger and regulator of a wide array of genes and proteins. ... -
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
(2022)Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records ... -
Using big data to assess prescribing patterns in Greece: The case of chronic obstructive pulmonary disease
(2016)Introduction: Chronic Obstructive Pulmonary Disease (COPD) is one of the top leading causes of death and disability, and its management is focused on reducing risk factors, relieving symptoms, and preventing exacerbations. ...